Linagliptin

CAS 668270-12-0 · Antidiabetic, DPP-4 inhibitor

Signals from filings dated January 2026 – October 2026 · Last checked 7 Nov 2026

Supply outlook

↑ GROWING

In the filings we track: 3 plants adding this molecule, 0 exit signals, 0 intermediate projects.

↑ Coming in3 plants+3 t/yr, where filed in tonnes
↓ Leaving0no drops or surrenders found
⇄ Own intermediates0no KSM projects found
Furthest stageHearingno clearance granted yet

Signals

Plot 46-47, Suvas Global Industrial Hub, Moraiya, Sanand, Ahmedabad, Gujarat

  1. ✓ Terms of reference
  2. ✓ Public hearing · 30 Oct 2026
  3. Next: clearance
  4. Consent to operate
  5. DMF / CEP

Listed in Group E (17 products, and/or): 36 t/yr shared across the group. Greenfield API unit, 283.2 t/yr in total. Public hearing held 30 Oct 2026. Source: EIA executive summary, GPCB

Sy. No. 667, Bhiknoor, Kamareddy, Telangana

  1. ✓ Terms of reference
  2. ✓ Public hearing · 7 Jan 2026
  3. Next: clearance
  4. Consent to operate
  5. DMF / CEP

New product at the site, 20 kg/day. Expansion of an approved API unit still under construction (EC 2021; taken over by Fusion Health Care in 2023). Worst case 6 products run at once; site total 1,000 to 2,420 kg/day. Public hearing held 7 Jan 2026. Source: EIA executive summary, TGPCB

Why capacity is shown as filed →

Who makes Linagliptin today: 33 listings

Current manufacturers with US DMF and CEP status, plant addresses and contacts.

See all manufacturers →
ManufacturerCountryUS DMFCEPContact
Alembic Pharmaceuticals LtdIndia✓—In database
Wisdom Pharmaceutical Co.,LTDUnited States✓—In database
Zhejiang Huahai Pharmaceutical Group Co LtdChina✓—In database
+ 30 more listings in api-fdf.com →

Three examples from the api-fdf.com database, refreshed weekly. Plant addresses and contacts are shown in the database.

Follow Linagliptin

Get an email when a new filing adds, cuts or moves this molecule to the next stage.

Follow

Other molecules with signals